View this post on Instagram
Eli Lilly and Company on Sunday announced positive results in the fight against breast cancer. A drug called Verzenio, also known as abemaciclib, in combination with adjuvant endocrine therapy, was said to “significantly” reduce the risk of breast cancer recurrence by 25% for those with a common subtype of breast cancer. The combo treatment also lowered the risk of developing metastatic disease by 28%, with the highest reduction rates to the liver and bone. Go to the link in our bio for more on this story.
Monday, September 21, 2020
Drug-therapy combo cuts breast cancer recurrence risk by 25%
at 6:06 PM